Study to know the efficacy of REMDESIVIR, an antiviral drug in treating Moderate and severe Covid ââ?¬â?? 19 Pneumonia (Lung Infection) due to CORONA virus in adult patients.
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B338- Other specified viral diseases
- Registration Number
- CTRI/2021/05/033742
- Lead Sponsor
- Government of Tamilnadu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Age ââ?°Â¥12 years with Confirmed COVID-19. (Laboratory (RT-PCR) ââ?¬â?? Positive)
Moderate COVID pneumonia:
Moderate Pneumonia (frequent fever, cough) with no obvious hypoxemia, chest CT with lesions.
Severe COVID pneumonia:
Severe Pneumonia with hypoxemia (SpO2 < 92%).
Patients received Remdesivir (Case) and also not received it (Control group).
Mild infection (without CT lesions)
Critical pneumonias (CT involvement > 75%).
Patients with moderate and Severe pneumonia but died within 3 days of hospital admission.
Patient who received Tocilizumab (critical pts)
Severe liver disease (AST > 5 times upper limit)
Patients with severe renal impairment (estimated GFR �30 mL/min/1.73 m2) or receiving continuous Dialysis
Pregnant or breastfeeding mothers.
Patient transferred to another hospital within 72 hours.
Cases with inadequate datas.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Time to clinical recovery <br/ ><br>2. All cause mortality <br/ ><br> <br/ ><br>Timepoint: one month
- Secondary Outcome Measures
Name Time Method 1. Duration of invasive mechanical ventilation <br/ ><br>2. Duration of noninvasive ventilation or use of high-flow Nasal oxygen devices (HFNO); <br/ ><br>3. Duration of low-flow supplemental oxygen; <br/ ><br>4. Any Complications (Drug or disease related), <br/ ><br>5. Length of hospital stay (days) <br/ ><br>Timepoint: One month <br/ ><br>